Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Nov 24, 2024; 15(11): 1412-1427
Published online Nov 24, 2024. doi: 10.5306/wjco.v15.i11.1412
Published online Nov 24, 2024. doi: 10.5306/wjco.v15.i11.1412
Potential regulatory mechanism and clinical significance of synaptotagmin binding cytoplasmic RNA interacting protein in colorectal cancer
Hui Li, Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
He-Qing Huang, Zhi-Guang Huang, Jia-Yuan Luo, Kai Qin, Dan-Ming Wei, Gang Chen, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Rong-Quan He, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Ye-Ying Fang, Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Rui Song, Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Da-Tong Zeng, Department of Pathology, Redcross Hospital of Yulin City, Yulin 537000, Guangxi Zhuang Autonomous Region, China
Co-first authors: Hui Li and He-Qing Huang.
Author contributions: Chen G and Wei DM contributed to the study conception and design; Material preparation, data collection and analysis were performed by Li H, Huang HQ, Huang ZG and He RQ; The first draft of the manuscript was written by Li H, Huang HQ, Fang YY, Song R, Luo JY, Zeng DT and Qin K commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Supported by Guangxi Zhuang Autonomous Region Health Commission Scientific Research Project , No. Z-A20220415 and No. Z20210442 ; and The First Affiliated Hospital of Guangxi Medical University Provincial and Ministerial Key Laboratory Cultivation Project: Guangxi Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer , No. 21-220-18 .
Institutional review board statement: Our study was approved by the medical ethics committee of the First Affiliated Hospital of Guangxi Medical University. The tissue microarray was purchased from Pantomics, Inc. (Richmond, CA, United States), and all the patients had completed the informed consent form.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: The data of this study can be obtained by contacting the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gang Chen, PhD, Professor, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, No. 22 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. chengang@gxmu.edu.cn
Received: March 24, 2024
Revised: August 17, 2024
Accepted: September 9, 2024
Published online: November 24, 2024
Processing time: 203 Days and 18.6 Hours
Revised: August 17, 2024
Accepted: September 9, 2024
Published online: November 24, 2024
Processing time: 203 Days and 18.6 Hours
Core Tip
Core Tip: Synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP) is regulated by enhancers and POLR2A and highly expressed in colorectal cancer (CRC). Highly expressed SYNCRIP can reduce CD8+ T cells and accelerate CRC cell division by exerting its epigenetic regulatory effects. These CRC cells are sensitive to radiation therapy. Finally, SYNCRIP is expected to become a biomarker in CRC patients.